1. Targeting Type 2 Diabetes
2. Dual Acting and Pan-PPAR Activators as Potential Anti-diabetic Therapies
3.GLP-1 Agonists and Dipeptidyl-Peptidase IV Inhibitors
4. Cannabinoids and Endocannabinoids in Metabolic Disorders with Focus on Diabetes
5. SGLT Inhibitors as New Therapeutic Tools in the Treatment of Diabetes
6. Inhibitors of 11β -Hydroxysteroid Dehydrogenase Type 1 in Antidiabetic Therapy
1. Targeting Type 2 Diabetes
p 1, nutrient excess and inflam modulate metabolism -> correct detrimental health -> obesity
lipid overload , immune response , proinflam pathway , organelle dysfn จาก excess adiposity -> เกิด type 2 DM
evidence linking – dysregulated CNS circuit – insulin resistance -> เกิด nutrient-sensing pathways – calorie restriction
therapeutic class of – biguanides , thiazolidinedione , incretin-base approach
p 2, 1. Inflam about obesity , Adipose Tissue and insulin resistance
2. Dual Acting and Pan-PPAR Activators as Potential Anti-diabetic Therapies
3.GLP-1 Agonists and Dipeptidyl-Peptidase IV Inhibitors
4. Cannabinoids and Endocannabinoids in Metabolic Disorders with Focus on Diabetes
5. SGLT Inhibitors as New Therapeutic Tools in the Treatment of Diabetes
6. Inhibitors of 11β -Hydroxysteroid Dehydrogenase Type 1 in Antidiabetic Therapy